Cabaletta Bio Q2 net loss widens as R&D costs rise

Cabaletta Bio

13/08/2026 12:42

Overview
U.S. biotech firm's Q2 net loss widened yr/yr as R&D expenses increased
Company ended Q2 with $225 mln in cash after May 2026 capital raise
Company expects cash to fund operations into mid-2027

Outlook
Company expects current cash position will fund operations into mid-2027

Result Drivers
INCREASED R&D SPENDING - Higher research and development expenses driven by advancement of rese-cel clinical trials across multiple autoimmune indications
MANUFACTURING PARTNERSHIPS - Expanded manufacturing agreements to support anticipated scale and supply chain resiliency for rese-cel

Company press release: ID:nGNX42ZGv3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.34
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cabaletta Bio, Inc. is $14.00, about 391.2% above its August 12 closing price of $2.85

Reuters Recommended Reads
Aug 12 - Turn Therapeutics Q2 net loss per share widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Scynexis Q2 swings to profit on warrant adjustment; advances drug studies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)